3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Leukemia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Kidney Neoplasms
1
High-risk Leukemias
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Filgrastim
4
Cyclophosphamide
4
Psychiatric Rehabilitation
3
Palliative Care
3
Busulfan
3
aflibercept
2
Vincristine
2
Thalidomide
2
Radiotherapy
2
Paclitaxel
2
Melphalan
2
Leucovorin
2
Irinotecan
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Docetaxel
2
Celecoxib
2
Azacitidine
2
Analgesia
2
venetoclax
1
trimetrexate glucuronate
1
tazemetostat
1
tanespimycin
1
sargramostim
1
romidepsin
1
ripretinib
1
pembrolizumab
1
liposomal doxorubicin
1
ixabepilone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Interleukin-15
×
Other hematologic neoplasm
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled